Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Postmarketing Study Oversight To Benefit From Informatics Upgrades

Executive Summary

Changes in legacy DARRTS system, transition to new platform and standardized format for annual report submission should improve FDA's tracking of postmarketing requirements, agency tells Office of the Inspector General.


Related Content

Pediatric Study Compliance Could Face Scrutiny In PDUFA Renewal
Do Drugs Given Expedited Approval Have More Safety Risks? GAO Says FDA Can't Tell
Merck’s Postmarketing Study Delays Prompt FDA To Unsheathe New Enforcement Power
FDA Should Fine Companies With Late Post-Marketing Studies, HHS OIG Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts